Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa, Japan.
J Neuroimmunol. 2019 Sep 15;334:577002. doi: 10.1016/j.jneuroim.2019.577002. Epub 2019 Jun 29.
Recently, we documented two Japanese cases of myelin-oligodendrocyte glycoprotein (MOG) antibody-associated relapsing encephalitis among patients who had been diagnosed with probable neuro-Behçet's disease (NBD). They presented partial systemic BD symptoms, brainstem lesions, and the human leukocyte antigen (HLA) B51 allele and responded well to steroid therapy. Our cases suggest that we need to differentiate anti-MOG antibody-associated encephalitis from probable NBD because both disorders can present with brainstem or cerebral lesions, CSF pleocytosis, and elevated levels of CSF IL-6 and respond to steroid treatment. Furthermore, oral ulceration, skin lesions, and HLA-B51 might be observed nonspecifically in patients with anti-MOG antibody-associated encephalitis.
最近,我们记录了两例日本患者,他们被诊断为可能的神经白塞病(NBD),患有髓鞘少突胶质细胞糖蛋白(MOG)抗体相关的复发性脑炎。他们表现出部分全身白塞病症状、脑干病变和人类白细胞抗原(HLA)B51 等位基因,对类固醇治疗反应良好。我们的病例表明,我们需要将抗 MOG 抗体相关脑炎与可能的 NBD 区分开来,因为这两种疾病都可能出现脑干或大脑病变、CSF 白细胞增多、CSF IL-6 水平升高,并对类固醇治疗有反应。此外,抗 MOG 抗体相关脑炎患者可能会出现口腔溃疡、皮肤损伤和 HLA-B51 非特异性表现。